Sort   by:  
 Page size 
UnknownUpdated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Not available
S-EPMC11084061 | biostudies-literature
UnknownAuthor Correction: Maladaptive positive feedback production of ChREBPβ underlies glucotoxic β-cell failure.
Not available
S-EPMC9515145 | biostudies-literature
UnknownMaladaptive positive feedback production of ChREBPβ underlies glucotoxic β-cell failure.
Not available
S-EPMC9339008 | biostudies-literature
UnknownARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Not available
S-EPMC10026083 | biostudies-literature
ProteomicsTau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic
Comparison of proteins from pooled CSF from 4 control mice and 5 VPS35 Camk2a KO mice
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2020-07-10 | MSV000085709 | MassIVE
UnknownUtility of Polygenic Risk Scores in Families with Exceptional Longevity.
Not available
S-EPMC12330441 | biostudies-literature
UnknownProfiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.
Not available
S-EPMC10806768 | biostudies-literature
UnknownEffect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Not available
S-EPMC2902875 | biostudies-literature
UnknownThe mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
Not available
S-EPMC4262609 | biostudies-literature
UnknownWhite matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Not available
S-EPMC10808262 | biostudies-literature
Sort   by:  
 Page size